Recombinant human mannose-binding lectin - NatImmune/Enzon

Drug Profile

Recombinant human mannose-binding lectin - NatImmune/Enzon

Alternative Names: rhMBL; rhMBL - NatImmune/Enzon

Latest Information Update: 13 Feb 2009

Price : $50

At a glance

  • Originator NatImmune
  • Developer Enzon Pharmaceuticals; NatImmune
  • Class Anti-infectives; Immunotherapies
  • Mechanism of Action Complement activation stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Infections

Most Recent Events

  • 11 Feb 2009 Discontinued - Phase-I for Infections in United Kingdom (IV)
  • 11 Feb 2009 Discontinued - Phase-I/II for Infections in USA (IV)
  • 13 Mar 2008 Recombinant human mannose-binding lectin (rhMBL) is still in phase I/II trials for prevention of infections in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top